GSK plc
CIK 1131399 · last filed 2025-12-15
GSK plc is a corporate insider who has filed 78 SEC Form 4 insider transactions across 30 companies since 2007. The most recent filing shows the insider bought $27.9M of WVE on Dec 15, 2025. Across all open-market trades the lifetime net is +$393.58T, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.90B across reported positions. The firm reports its address in London. 15 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.90B
Companies
30
Total Filings
78
Lifetime Open-Market Net
$393582.69B
Filer Profile
Reported Address
79 NEW OXFORD STREETLONDON WC1A 1DG
Phone
44 20 8047 5000
State of Incorporation
United Kingdom
Formerly Known As
GLAXOSMITHKLINE PLC (2001–2022)
Related Filers
Innoviva, Inc. — 15 joint filings, latest 2021-05-25
FMR LLC — 1 joint filings, latest 2026-05-06
Maria E Martinez — 1 joint filings, latest 2026-08-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WVE | 10%+ Owner | 18,245,691 | $4.59 | $83.75M | $66.77M | 3 | 2025-12-15 |
| TBPH | 10%+ Owner | 0 | $17.01 | $0 | $29986.81B | 4 | 2022-09-20 |
| CVRX | 10%+ Owner | 33,316 | $2.88 | $96.0K | $4.95M | 1 | 2021-07-06 |
| LYEL | 10%+ Owner | 1,512,659 | $11.96 | $18.09M | $0 | 1 | 2021-06-23 |
| INVA | 10%+ Owner | 0 | $20.66 | $0 | -$392.06M | 1 | 2021-05-24 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 1,183,663 | $4.91 | $5.81M | $2.70M | 1 | 2021-02-19 |
| BCYC | Director | 1,910,531 | $3.86 | $7.37M | $5.31M | 2 | 2020-09-18 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 4,626,389 | $0.00 | $2.8K | $11.06M | 3 | 2020-07-30 |
| Pandion Therapeutics, Inc. (PAND) Delisted | Director | 1,538,724 | $60.05 | $92.40M | $6.50M | 1 | 2020-07-22 |
| NKTX | Director | 604,589 | $2.91 | $1.76M | $15.00M | 1 | 2020-07-16 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 2,253,660 | $76.01 | $171.30M | $18.85M | 3 | 2020-05-26 |
| PGNY | 10%+ Owner | 6,238,244 | $27.35 | $170.62M | -$103.00M | 2 | 2020-05-21 |
| Principia Biopharma Inc. (PRNB) Delisted | 10%+ Owner | 2,982,855 | — | — | $14.59M | 4 | 2019-10-22 |
| FULC | 10%+ Owner | 1,785,714 | $3.80 | $6.79M | $0 | 1 | 2019-07-24 |
| Morphic Holding, Inc. (MORF) Delisted | Director | 2,633,772 | $56.99 | $150.10M | $5.00M | 1 | 2019-07-02 |
| CCXI | 10%+ Owner | 0 | $12.32 | $0 | -$85.85M | 2 | 2018-10-18 |
| SPRO | 10%+ Owner | 1,934,006 | $1.13 | $2.19M | $7.00M | 2 | 2018-07-17 |
| Translate Bio, Inc. (TBIO) Delisted | 10%+ Owner | 165,230 | $0.00 | $17 | $3.50M | 1 | 2018-07-03 |
| HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | 10%+ Owner | 4,404 | $0.48 | $2.1K | -$978.9K | 3 | 2017-03-30 |
| CRISPR Therapeutics AG (PZRX) Delisted | 10%+ Owner | 3,154,127 | — | — | $931.0K | 2 | 2016-10-26 |
| Innoviva, Inc. (THRX) Delisted | 10%+ Owner | 32,005,260 | $4.06 | $129.94M | $363597.22B | 20 | 2015-08-07 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | 10%+ Owner | 1,436,448 | $0.39 | $565.4K | -$12.13M | 2 | 2015-02-24 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 0 | $14.49 | $0 | -$38.29M | 3 | 2014-10-28 |
| PATH | 0 | $13.75 | $0 | $0 | 1 | 2014-02-24 | |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 1,356,533 | $8.37 | $11.35M | $490.0K | 1 | 2014-02-20 | |
| HUMAN GENOME SCIENCES INC (HGSI) Delisted | Director | 171,070,522 | — | — | $1.07B | 2 | 2012-08-03 |
| DGX | Director | 15,377,551 | $235.02 | $3.61B | -$1.95B | 4 | 2011-02-02 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | 10%+ Owner | 2,771,374 | $10.19 | $28.24M | $5.00M | 1 | 2010-11-24 |
| Redpoint Bio CORP (BDSI) Delisted | 10%+ Owner | — | $5.59 | — | $0 | 1 | 2010-03-16 |
| EPIX Pharmaceuticals, Inc. (EPIX) Delisted | 10%+ Owner | 227,962 | $0.20 | $45.9K | $0 | 1 | 2007-12-20 |
Recent Filings
78 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-15 | WVE | Buy (P) | +1,470,000 | $27.93M | EDGAR |
| 2024-10-01 | WVE | Buy (P) | +2,791,930 | $22.34M | EDGAR |
| 2024-01-30 | WVE | Buy (P) | +3,300,000 | $16.50M | EDGAR |
| 2022-09-20 | TBPH | Other (J) | −9,644,807 | -$94.04M | EDGAR |
| 2021-07-06 | CVRX | Mixed | +975,772 | $4.95M | EDGAR |
| 2021-06-23 | LYEL | Conv (C) | +30,253,189 | $0 | EDGAR |
| 2021-05-24 | INVA | Sell (S) | −32,005,260 | -$392.06M | EDGAR |
| 2021-02-19 | Decibel Therapeutics, Inc. (DBTX) Delisted | Mixed | +1,183,663 | $2.70M | EDGAR |
| 2020-09-18 | BCYC | Sell (S) | −4,744 | -$91.8K | EDGAR |
| 2020-07-30 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Buy (P) | +1,260,504 | $2.84M | EDGAR |
Showing 1–10 of 78
Page 1 of 8
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.